Search Articles Directory Grenada: Exelon

Exelon is a brand name of rivastigmine, approved by the FDA in the following formulation(s):

EXELON (rivastigmine - film, extended release; transdermal)

Manufacturer: NOVARTIS

Approval date: July 6, 2007

Strength(s): 4.6MG/24HR, 9.5MG/24HR ^[RLD]

EXELON (rivastigmine tartrate - capsule; oral)

Manufacturer: NOVARTIS

Approval date: April 21, 2000

Strength(s): EQ 1.5MG BASE ^[RLD]^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

EXELON (rivastigmine tartrate - solution; oral)

Manufacturer: NOVARTIS

Approval date: April 21, 2000

Strength(s): EQ 2MG BASE/ML ^[RLD]

Has a generic version of Exelon been approved?

A generic version of Exelon has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Exelon and have been approved by the FDA:

rivastigmine tartrate capsule; oral

Manufacturer: DR REDDYS LABS INC

Approval date: October 31, 2007

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: October 22, 2007

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: January 8, 2008

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Note: No generic formulation of the following products are available.

rivastigmine - film, extended release; transdermal

rivastigmine tartrate - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exelon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Phenyl carbamates
Patent 4,948,807
Issued: August 14, 1990
Inventor(s): Rosin; Marta W. & Chorev; Michael & Tashma; Zeev
Assignee(s): Proterra AG
Phenyl carbamates of the general formula ##STR1## wherein R.sub.1 to R.sub.5 are as defined in the claims, are useful as pharmaceuticals.
Patent expiration dates:
- August 14, 2012
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
  ✓
  Drug substance

Phenyl carbamate
Patent 5,602,176
Issued: February 11, 1997
Inventor(s): Enz; Albert
Assignee(s): Sandoz Ltd.
The (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenylncarbamate in free base or acid addition salt form is useful as pharmaceutical, particularly for systemic transdermal administration.
Patent expiration dates:
- February 11, 2014
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
  ✓
  Drug substance
  ✓
  Drug product
- February 11, 2014
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA

TTS containing an antioxidant
Patent 6,316,023
Issued: November 13, 2001
Inventor(s): Asmussen; Bodo & Horstmann; Michael & Kopke; Kai & Tiemessen; Henricus L. G. M. & Dinh; Steven Minh & Gargiulo; Paul M.
Assignee(s): Novartis AG
LTS Lohmann Therapie-Systeme GmbH
Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Patent expiration dates:
- January 8, 2019
  ✓
  Drug product

TTS containing an antioxidant
Patent 6,335,031
Issued: January 1, 2002
Inventor(s): Bodo; Asmussen & Michael; Horstmann & Kai; Köpke & Henricus L. G. M.; Tiemessen & Steven Minh; Dinh & Paul M.; Gargiulo
Assignee(s): Novartis AG
LTS Lohmann Therapie-Systeme GmbH Co. KG
Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Patent expiration dates:
- January 8, 2019
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- July 6, 2010 - NEW DOSAGE FORM

Search Articles Directory Grenada

Thursday, 9 April 2009

Exelon